Aurinia Pharmaceuticals Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc. on June 9, 2016. The filing serves as a report of a foreign private issuer pursuant to Rule 13A-16 or 15D-16 under the Securities Exchange Act of 1934. The document primarily discloses the results of the company's Annual General Meeting.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance events rather than financial performance data.
Material Changes
No material financial changes versus the prior comparable period are disclosed in this specific filing. The content is limited to the announcement of voting results from the Annual General Meeting.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It includes an exhibit index referencing a news release regarding the Annual General Meeting results and a report of voting results.
Key Facts for Investors to Verify
- Verify the specific voting outcomes detailed in the attached "Report of Voting Results" (Exhibit 99.2).
- Confirm the details of the Annual General Meeting as described in the referenced news release (Exhibit 99.1).
- Note that this filing does not contain updated financial statements; refer to the most recent Form 40-F or quarterly reports for financial data.